Adis, a Wolters Kluwer Business, Auckland, New Zealand.
Drugs. 2010 Feb 12;70(3):355-76. doi: 10.2165/11202860-000000000-00000.
Trabectedin (Yondelis) is a tetrahydroisoquinoline molecule that was originally derived from a marine organism. It is indicated in the EU and many other countries for use in patients with advanced soft-tissue sarcoma (STS) who have progressed despite receiving previous treatment with anthracyclines and ifosfamide or in those who are unable to receive these agents. It is also approved in the EU in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer. In addition, trabectedin holds orphan drug status for the treatment of advanced, recurrent STS in the US, Switzerland and Korea, and for the treatment of advanced, recurrent ovarian cancer in the US and Switzerland. Clinical trials showed that intravenous trabectedin was effective in chemotherapy-experienced patients with advanced, recurrent liposarcoma or leiomyosarcoma, and results from a retrospective analysis suggest that the drug may be particularly effective in patients with advanced myxoid liposarcoma. In addition, coadministration of trabectedin with pegylated liposomal doxorubicin was associated with a significantly longer progression-free survival (6 weeks) than pegylated liposomal doxorubicin monotherapy in patients with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. The tolerability profile of trabectedin was manageable in clinical trials, and the tolerability profile of concomitant trabectedin and pegylated liposomal doxorubicin was generally consistent with that of each agent alone. Results to date indicate that trabectedin is a valuable addition to the group of second-line antineoplastic agents available for the treatment of advanced, recurrent STS, and that it is a beneficial treatment for recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy when administered in conjunction with pegylated liposomal doxorubicin.
曲贝替定（Yondelis）是一种四氢异喹啉分子，最初来源于海洋生物。它在欧盟和许多其他国家被批准用于治疗接受蒽环类和异环磷酰胺治疗后进展的晚期软组织肉瘤（STS）患者，或不能接受这些药物的患者。它还在欧盟被批准与聚乙二醇化脂质体阿霉素联合用于治疗铂敏感的复发性卵巢癌。此外，曲贝替定在美国、瑞士和韩国被批准用于治疗晚期复发性 STS 的孤儿药，在美国和瑞士被批准用于治疗晚期复发性卵巢癌。临床试验表明，静脉注射曲贝替定对化疗后晚期复发性脂肪肉瘤或平滑肌肉瘤患者有效，回顾性分析结果表明，该药物可能对晚期黏液样脂肪肉瘤患者特别有效。此外，曲贝替定与聚乙二醇化脂质体阿霉素联合使用与聚乙二醇化脂质体阿霉素单药治疗相比，在一线铂类化疗失败后的复发性卵巢癌患者中，无进展生存期（6 周）显著延长。在临床试验中，曲贝替定的耐受性良好，曲贝替定与聚乙二醇化脂质体阿霉素联合使用的耐受性与单独使用每种药物的耐受性大致一致。迄今为止的结果表明，曲贝替定是治疗晚期复发性 STS 的二线抗肿瘤药物中的一个有价值的补充，当与聚乙二醇化脂质体阿霉素联合使用时，它是铂类化疗失败后的复发性卵巢癌的一种有益的治疗方法。
